For Patients: Our Phase I trial is currently enrolling!
Precision Oncology, Simplified.
Practical, impactful, and immediately valuable small molecule therapeutics for cancer.
We are clinical-stage biotechnology company advancing small molecule therapeutics for cancer treatment.
Discover Our Approach
Our Therapeutic Philosophy
At Jabez Biosciences, we believe cancer therapy can be highly potent while ALSO being convenient and practical. That’s why our strategy centers on identifying and advancing small molecule therapeutics that integrate naturally and effectively with existing treatments. We carefully select compounds known for their potency, favorable safety potential, and ease of use, positioning them as ideal therapeutic additions to existing oncology regimens.
Our Clinical Trials
We are actively pursuing clinical investigations in various solid tumor indications and non-Hodgkin lymphoma (NHL), reflecting our commitment to addressing a broad spectrum of oncological needs. Explore our pipeline to see our current and future plans.
Useful Links
News & Media
Stay up to date on our latest news, events, and presentations. Visit our media center to get all the updates.
Investors
We’re actively seeking funding to fuel the advancement of our clinical trials. Click the link below to become a contributing member of the Jabez team
Contact
Looking to get in direct contact with out team? Click the link below to send us a message.
Our Product Roadmap
Charting the course for our DHODH inhibitor, JBZ-001
June 2024
Phase I Readiness
Our DHODH inhibitor, JBZ-001, is Phase I ready with comprehensive pre-clinical data supporting its therapeutic potential
June 2024
IND Filing
We filed an Investigational New Drug (IND) application to the FDA, marking a significant milestone in our development process.
Dec. 2024
Study Start
The clinical study is expected to commence, bringing us closer to offering a new treatment option for cancer patients
First-Line Treatment Potential
JBZ-001 is anticipated to be a first-line treatment for various tumor types, with potential FDA Fast-Track designation and priority review status.
FDA Review
We aim to achieve FDA Fast-Track designation, priority review, and Orphan-Drug status for JBZ-001, expediting the review process.
Market Launch
Following successful trials and regulatory approvals, we plan to launch JBZ-001, providing new hope for cancer patients worldwide.